HIL-214
Prevention of moderate-to-severe acute gastroenteritis caused by norovirus infection
Key Facts
About HilleVax
HilleVax is a clinical-stage biotech focused on developing and commercializing novel vaccines, with a lead program targeting norovirus-induced acute gastroenteritis. The company's core asset, HIL-214, is advancing through Phase 2b/3 and Phase 2 trials, aiming to address a large, underserved global market. Founded by former Takeda Vaccines leaders, HilleVax's strategy hinges on leveraging its team's proven expertise in vaccine development and commercialization. As a pre-revenue public company, its near-term value is tied to the clinical and regulatory success of HIL-214.
View full company profileAbout HilleVax
HilleVax is a clinical-stage biotech focused on developing and commercializing novel vaccines, with a lead program targeting norovirus-induced acute gastroenteritis. The company's core asset, HIL-214, is advancing through Phase 2b/3 and Phase 2 trials, aiming to address a large, underserved global market. Founded by former Takeda Vaccines leaders, HilleVax's strategy hinges on leveraging its team's proven expertise in vaccine development and commercialization. As a pre-revenue public company, its near-term value is tied to the clinical and regulatory success of HIL-214.
View full company profile